Janux Therapeutics Announces Departure of Chief Strategy Officer
I'm PortAI, I can summarize articles.
Janux Therapeutics Inc (JANX) announced the departure of Byron Robinson, Ph.D., as Chief Strategy Officer, effective September 18, 2025, classified as a termination without ‘Cause’. The current analyst rating for JANX stock is a Hold with a price target of $24.50. Spark’s AI Analyst rates JANX as Neutral, citing strong revenue growth but ongoing profitability challenges. The stock has a market cap of $1.41B and an average trading volume of 772,841.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments